What the Study Found (In Plain English)
Published in Human vaccines & immunotherapeutics (2026), this phase iii randomized trial evaluating 10,000 human participants investigated: SARS-CoV-2 neutralizing antibodies (nAbs) are strongly inversely associated with COVID-19 risk and have correlated with vaccine efficacy across multiple clinical trials conducted during the COVID-19 pandemic. Key clinical takeaway: The estimated hazard ratios per 10-fold increase in Day 29 nAbs against D614G, BA.4/BA.5, and XBB.1.5 were 0.70 (95% confidence interval [CI]: 0.48-1.02; p = .064), 0.49 (95% CI: 0.41-0.58; p p < .001), respectively.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Human vaccines & immunotherapeutics, 2026-12-15; N = 10000; Rigor 90/100): The estimated hazard ratios per 10-fold increase in Day 29 nAbs against D614G, BA.4/BA.5, and XBB.1.5 were 0.70 (95% confidence interval [CI]: 0.48-1.02; p = .064), 0.49 (95% CI: 0.41-0.58; p p < .001), respectively.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Phase III Randomized Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.